"Right to try" laws

Clinical Trials

Volumn 11, Issue 5, 2014, Pages 519-520

  Begg, Colin B ^a   Kim, Kyung Mann ^b   Neaton, James D ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); DRUG SCREENING; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE ACCESS; HUMAN; LAW; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED KINGDOM; UNITED STATES; COMPASSIONATE USE; DRUG APPROVAL; LEGISLATION AND JURISPRUDENCE; PATIENT RIGHT;

COMPASSIONATE USE TRIALS; DRUG APPROVAL; HUMANS; PATIENT RIGHTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84927768384     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774514546574     Document Type: Editorial

References (3)

1. Servick K.Patient advocacy. "Right to Try" laws bypass FDA for last-ditch treatments. Science 2014; 344: 1329.
2. Society for Clinical Trials Board of Directors. The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. Clin Trials 2006; 3: 154-157.
3. US Food and Drug Administration. CFR-Code of Federal Regulations Title 21, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312 &showFR=1&subpartNode=21:5.0.1.1.3.9 (2013, accessed 2 July 2014).